Mupina (Mupirocin)

Mupirocin blocks the bacterial enzyme isoleucyl‑tRNA synthetase, preventing the incorporation of isoleucine into proteins. This halts protein synthesis, inhibiting bacterial growth. At higher concentrations it can kill bacteria, making it effective against Gram‑positive organisms such as Staphylococcus aureus.

The dosage and duration of Mupina are determined by the prescribing clinician based on the patient’s condition and local guidelines. Typical regimens involve applying a small amount of the nasal preparation twice daily for a defined period, but exact instructions must come from a qualified health professional.

Safety data for intranasal mupirocin in pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits against any possible risks before prescribing Mupina to pregnant or breastfeeding individuals.

To order Mupina, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Mupina (mupirocin) offers targeted activity against Staphylococcus aureus, including MRSA, with a low risk of systemic side effects due to minimal absorption. Alternatives such as povidone‑iodine or chlorhexidine have broader antimicrobial spectra but may cause more irritation. Choice depends on resistance patterns, patient tolerance and clinical guidelines.

Store Mupina at room temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct light. Keep the container tightly closed when not in use and avoid exposing it to extreme temperatures.

Mupina is applied intranasally. The prescribed amount is placed into each nostril using the supplied applicator, usually twice daily, for the duration indicated by the prescriber. Patients should avoid blowing their nose immediately after application to allow adequate contact time.

Although rare, serious adverse reactions can include allergic contact dermatitis, anaphylaxis and severe skin reactions such as Stevens‑Johnson syndrome. Any signs of severe rash, swelling, difficulty breathing or systemic symptoms should prompt immediate medical attention.

Mupina should be avoided in individuals with a known hypersensitivity to mupirocin or any excipients in the formulation. It is also contraindicated on severely damaged or ulcerated nasal mucosa and should be used with caution in patients with extensive skin conditions or compromised immunity.